Skip to main content
Clinical Trials/NCT02078479
NCT02078479
Completed
N/A

Repetitive Transcranial Magnetic Stimulation in Neuropathic Pain Secondary to Malignancy.

Assiut University0 sites34 target enrollmentJanuary 2010
ConditionsMalignancy

Overview

Phase
N/A
Intervention
Not specified
Conditions
Malignancy
Sponsor
Assiut University
Enrollment
34
Primary Endpoint
Neuropathic pain improvement
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

The purpose of this study isto assess the efficacy of daily 10 sessions of rTMS over primary motor cortex in patients suffering from malignant neuropathic pain. Thirty four patients were divided randomly into 2 groups equally using closed envelops to undergo real (20 Hz, 10 second, 10 trains with inter-train interval 30 second with total pulses 2000, intensity 80% of motor threshold over hand area of motor cortex) or sham rTMS (same parameters but with coil elevated and angled away from the head)every day for ten consecutive days (5 days/week). Patients were evaluated using a verbal descriptor scale (VDS), visual analog scale (VAS), Leeds assessment of neuropathic symptoms and signs (LANSS) and Hamilton rating scale for depression (HAM-D) at baseline, after 1st, 5th, 10thtreatment session, and then 15 days and 1 month after the end of treatment. ic pain.

Registry
clinicaltrials.gov
Start Date
January 2010
End Date
May 2013
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Eman M. Khedr

Clinical Professor

Assiut University

Eligibility Criteria

Inclusion Criteria

  • All patients within age group 18-65 years with malignant lateralized neuropathic pain resistant to medical treatment for at least 2 months or associated with significant adverse effects from medication were involved in this study.

Exclusion Criteria

  • Patients with intracranial metallic devices Patients with pacemakers or any other device. Patients with recent myocardial ischemia, unstable angina Patients known to have history of epilepsy.

Outcomes

Primary Outcomes

Neuropathic pain improvement

Time Frame: one month

Reduction of neuropathic pain in patients with malignancy measured by VDS, VAS, LANSS.

Secondary Outcomes

  • Reduction of depression manifestation(one month)

Similar Trials